<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471741</url>
  </required_header>
  <id_info>
    <org_study_id>MARA-2</org_study_id>
    <nct_id>NCT03471741</nct_id>
  </id_info>
  <brief_title>Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer</brief_title>
  <official_title>Moderated Accelerated RAdiotherapy (MARA-2) in Moderate-high Risk Breast Cancer: a Phase I-II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk
      breast cancer in terms of late toxicity and local control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients treated conservatively with moderate-high risk breast cancer were treated with IMRT
      plus concomitant boost to surgical bed (up to a dose of 50 Gy to whole breast and 60 Gy to
      the tumor bed).

      Aim of the study was to evaluate late toxicity and local control after this treatment
      compared with a historical control group (CG) of patients treated with 3D-conformal
      postoperative radiotherapy delivered with conventional fractionation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2001</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment.related late adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>late toxicity (cutaneous and subcutaneous) is evaluated using RTOG/EORTC criteria in both groups of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>5 years</time_frame>
    <description>absence of locoregional relapse</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">451</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <arm_group>
    <arm_group_label>MARA-2: IMRT with concomitant boost</arm_group_label>
    <description>A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CG: 3D-RT with sequential boost</arm_group_label>
    <description>The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT with concomitant boost</intervention_name>
    <arm_group_label>MARA-2: IMRT with concomitant boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3D-RT with sequential boost</intervention_name>
    <arm_group_label>CG: 3D-RT with sequential boost</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        From 2003, all women fullfilling the inclusion criteria were treated with MARA-2 scheme
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed invasive breast cancer (pT1-4) with at least one of these
             characteristics: 3 or more metastatic axillary nodes, pre or peri-menopausal status,
             close resection margins

          -  breast conservative surgery

        Exclusion Criteria:

          -  positive margins

          -  distant metastases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio G Morganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine-DIMES, Unversity of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Alessio Giuseppe Morganti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>cutaneous toxicity</keyword>
  <keyword>subcutaneous toxicity</keyword>
  <keyword>local control</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

